Journal article

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration.

Susan F Hurley, Jane P Matthews, Robyn H Guymer

Cost Effectiveness and Resource Allocation | Published : 2008

Abstract

BACKGROUND: Intravitreal ranibizumab prevents vision loss and improves visual acuity in patients with neovascular age-related macular degeneration, but it is expensive, and efficacy beyond 2 years is uncertain. METHODS: We assessed the cost-effectiveness of ranibizumab compared with no ranibizumab over 10 years, using randomized trial efficacy data for the first 2 years, post-trial efficacy assumptions, and ranibizumab acquisition costs ranging from the wholesale price ($1,950 per dose) to the price of bevazicumab ($50), a similar molecule which may be equally efficacious. We used a computer simulation model to estimate the probability of blindness, the number of quality-adjusted lif..

View full abstract

Grants

Citation metrics